Anti-CEA [CH1A1A (2F1, CH1A1A-2F1)]

Absolute Antibody

Anti-CEA [CH1A1A (2F1, CH1A1A-2F1)]

7

CH1A1A is a humanized, affinity matured, and stability-engineered version derived from the murine parental PR1A3 antibody, first disclosed in PMID: 2434440. This antibody is also basis of CEA TCB (RG7802), a CEA-CD3 T cell bispecific antibody currently in Phase 1/1b clinical trials (PMID: 27622073; 27117182; 26861458). This antibody was also used in the generation of cergutuzumab amunaleukin (CEA-IL2v, RG7813), a monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc mediated effector functions. The binding affinity of this antibody for CEA was tested using ELISA. This antibody can also be used in the immunohistochemical analysis of CEA expression by various tumors (PMID: 28405498). This antibody was also used to study the surface expression heterogeneity of CEA in cells extracted from patient derived colorectal cancer organoids (PDOs) using flow cytometry (PMID: 30982469).

Flow Cytometry, ELISA, ImmunoHistoChemistry

ELISA; FC; IHC

Research Use Only

Monoclonal

CH1A1A (2F1, CH1A1A-2F1)

CEACAM5

CEA cell adhesion molecule 5

carcinoembryonic antigen related cell adhesion molecule 5; carcinoembryonic antigen-related cell adhesion molecule 5; CD66e; CEA; meconium antigen 100

Human

IgG1

Carcinoembryonic antigen-related cell adhesion molecule 5

Human

The original murine antibody PR.1A3 was generated by immunizing BALB/c mice with mucosal scrapings and cell membrane preparations from normal large intestine. Booster dose was given with same antigen or in one case boosting was also performed with HT29 colon carcinoma cells. CH1A1A was later one generated for affinity maturation and stability enhancement by phage display.

-20°C,2°C to 8°C

12352203